AnaptysBio (ANAB) Competitors

AnaptysBio (NASDAQ:ANAB) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Do insiders and institutionals believe in ANAB or APLS?

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has stronger valuation & earnings, ANAB or APLS?

AnaptysBio has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$91.28M	6.13	-$145.23M	-$4.48	-4.46
Apellis Pharmaceuticals	$781.37M	4.46	-$197.88M	-$1.82	-15.18

Does the media favor ANAB or APLS?

In the previous week, AnaptysBio had 17 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 24 mentions for AnaptysBio and 7 mentions for Apellis Pharmaceuticals. AnaptysBio's average media sentiment score of 0.91 beat Apellis Pharmaceuticals' score of 0.66 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apellis Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, ANAB or APLS?

AnaptysBio has a beta of -0.2, indicating that its share price is 120% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Is ANAB or APLS more profitable?

Apellis Pharmaceuticals has a net margin of -30.24% compared to AnaptysBio's net margin of -107.66%. Apellis Pharmaceuticals' return on equity of -116.09% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-107.66%	-366.98%	-30.58%
Apellis Pharmaceuticals	-30.24%	-116.09%	-26.72%

Do analysts prefer ANAB or APLS?

AnaptysBio currently has a consensus price target of $46.13, indicating a potential upside of 130.97%. Apellis Pharmaceuticals has a consensus price target of $34.12, indicating a potential upside of 23.53%. Given AnaptysBio's stronger consensus rating and higher possible upside, equities analysts clearly believe AnaptysBio is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80
Apellis Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

AnaptysBio and Apellis Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.